Abstract： Objective： To observe the clinical efficacy of Jiangzhi Prescription combined with Atorvastatin Calcium in treating hyperlipidemia（HLP）of phlegm-turbidity obstruction type. Methods：A total of 104 HLP patients of phlegm-turbidity obstruction type treated in Anji County Hospital of Chinese Medicine from January 2023 to December 2024 were selected and randomly divided into the control group and the observation group using the random number table method，with 52 cases in each group. During the study period，in the control group，three cases were withdrawn and one case was excluded，in the observation group，one case was withdrawn and one case was excluded. Finally，48 cases in the control group and 50 cases in the observation group completed the study. The control group was treated with Atorvastatin Calcium Tablets，and the observation group was treated with Jiangzhi Prescription on the basis of the control group. Both groups were treated for four weeks. The clinical efficacy， as well as traditional Chinese medicine syndrome scores， blood lipid indexes [total cholesterol（TC）， triglyceride（TG）， high density lipoprotein cholesterol（HDL-C）， and low density lipoprotein cholesterol（LDL-C）]， vascular endothelial function [nitric oxide （NO）， endothelin-1（ET-1）， and thromboxane B2（TXB2）]， obesity morphological indexes [body weight（BW）， body mass index（BMI）， and waist circumference（WC）] before and after treatment and the incidence of adverse reactions during the treatment were compared between the two groups. Results: After treatment，the total effective rate in the observation group was 94.00%（47/50），which was higher than that of 79.17%（38/48）in the control group（P＜ 0.05）. The scores of body obesity， emesis of phlegm and saliva， chest tightness， heaviness of the head as being swathed， limb numbness and heaviness sensation， insomnia， palpitation， bland taste in the mouth， and low food intake and total scores in the two groups decreased compared with those before treatment（P＜0.05）. The scores of body obesity，emesis of phlegm and saliva，chest tightness，heaviness of the head as being swathed，limb numbness and heaviness sensation， insomnia， palpitation， bland taste in the mouth， and low food intake and total scores in the observation group were lower than those in the control group（P＜0.05）. The levels of serum TG，TC and LDL-C in the two groups decreased compared with those before treatment（P＜0.05），and the levels of serum TG，TC and LDL-C in the observation group were lower than those in the control group（P＜0.05）. The level of serum HDL-C in the two groups increased compared with that before treatment（P＜0.05），and the level of serum HDL-C in the observation group was higher than that in the control group（P＜0.05）. The level of serum NO in the two groups increased compared with that before treatment（P＜0.05）， and the level of serum NO in the observation group was higher than that in the control group（P＜0.05）. The levels of serum ET-1 and TXB2 in the two groups decreased compared with those before treatment，and the levels of serum ET-1 and TXB2 in the observation group were lower than those in the control group （P＜0.05）. The levels of BW，BMI and WC in the observation group decreased compared with those before treatment （P＜0.05），and the levels of BW，BMI and WC in the observation group were lower than those in the control group （P＜0.05）. There was no significant difference being found in the levels of BW， BMI and WC in the control group compared with those before treatment（P＞0.05）. During the treatment， the incidence of adverse reactions in the observation group was 4.00%（2 / 50）， which was lower than 18.75%（9 / 48） in the control group（P＜0.05）. Conclusion： The combination of Jiangzhi Prescription and Atorvastatin Calcium has a good clinical effect in the treatment of HLP of phlegm turbidity obstruction type，which can effectively relieve clinical symptoms，regulate blood lipid level，improve vascular endothelial function，reduce obesity degree，and has good safety.